Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data from Its Nurelin™ Program at American Academy of Neurology Conference Emeryville, Calif., March 20, 2013 - Adamas Pharmaceuticals, Inc. will present research results today from its Nurelin™ (amantadine HCl extended release capsules)
Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer’s Disease NEW YORK & EMERYVILLE, CA, November 13, 2012 - Forest Laboratories, Inc.
Adamas Pharmaceuticals Presents Update On NurelinTM Program At Cambridge Healthtech Institute’s Parkinson’s Conference. EMERYVILLE, CALIF., June 4, 2012 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its NurelinTM (amantadine HCl extended
Adamas Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For ARIMENDATM EMERYVILLE, CALIF., May 15, 2012 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has held an End-of-Phase 2 meeting with the FDA to discuss the proposed safety and efficacy
Adamas Pharmaceuticals Initiates A Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease EMERYVILLE, CALIF., September 28, 2011 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug
Adamas Pharmaceuticals' TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible And Resistant Strains Of Influenza In Animal Models EMERYVILLE, CALIF., - March 15, 2010 - Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in
Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy Is More Potent Than Double Combinations Or Monotherapy Against Drug-Resistant Flu Strains Emeryville, Calif. - February 22, 2010 - Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of
Adamas Pharmaceuticals Signs CRADA with U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including The Novel H1N1 Pandemic Strain Emeryville, Calif., - August 18, 2009 - Adamas Pharmaceuticals, Inc., a privately held company, announced today